Enliven Therapeutics, Inc. (ELVN)
NASDAQ: ELVN · Real-Time Price · USD
20.27
-0.73 (-3.48%)
At close: Mar 10, 2025, 4:00 PM
22.27
+2.00 (9.88%)
After-hours: Mar 10, 2025, 4:08 PM EST
Enliven Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Enliven Therapeutics stock have an average target of 37.8, with a low estimate of 34 and a high estimate of 42. The average target predicts an increase of 86.48% from the current stock price of 20.27.
Analyst Consensus: Strong Buy
* Price targets were last updated on Dec 13, 2024.
Analyst Ratings
The average analyst rating for Enliven Therapeutics stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 4 | 4 | 4 | 4 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BTIG | BTIG | Strong Buy Initiates $42 | Strong Buy | Initiates | $42 | +107.20% | Dec 13, 2024 |
| Baird | Baird | Buy Maintains $32 → $40 | Buy | Maintains | $32 → $40 | +97.34% | Nov 15, 2024 |
| Jones Trading | Jones Trading | Strong Buy Initiates $36 | Strong Buy | Initiates | $36 | +77.60% | Oct 31, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $37 | Strong Buy | Reiterates | $37 | +82.54% | Oct 1, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $37 | Strong Buy | Initiates | $37 | +82.54% | Sep 9, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
8.50K
EPS This Year
-1.99
from -2.01
EPS Next Year
-2.40
from -1.99
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | n/a | 52,500 | 52,500 | |||
| Avg | n/a | 8,497 | 8,497 | |||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | 517.9% | |||
| Avg | - | - | - | |||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | -2.02 | -1.79 | -1.84 | |
| Avg | -1.99 | -2.40 | -2.74 | |
| Low | -1.96 | -2.67 | -3.58 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | - | - | - | |
| Avg | - | - | - | |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.